What did @everydaywithsarahd actually say?
The creator argues that pairing retatrutide (which she calls "Reddit" throughout) with MOTSC is effective because the two compounds work on distinct fat-loss mechanisms. Retatrutide, she says, works at the hormone level by targeting hunger signals and improving insulin function. MOTSC, which she correctly identifies as a mitochondrial peptide, supposedly helps cells burn fuel more efficiently and counteracts the energy dip some people experience on GLP-1 receptor agonists.
She specifically claims retatrutide "increases your GLP, your GIP, and your blue loon" (likely glucagon), and that MOTSC "allows the glucose and the fat to get into the cell instead of storing it as fat." She also claims MOTSC boosts energy, which she frames as a practical fix for fatigue associated with retatrutide use.
The framing is casual but mechanistically specific, and that specificity is worth examining closely. Some of it holds up. Some of it does not.
Does the science back this up?
Partially, but the evidence is asymmetric. Retatrutide's mechanism is reasonably well-described in published data. MOTSC's human evidence is thin, and the combination has no controlled study behind it.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. A Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) found participants lost up to 17.5% of body weight over 24 weeks, with effects attributed to appetite suppression, improved insulin sensitivity, and increased energy expenditure via glucagon receptor activation. So the broad strokes of her hormonal explanation are grounded in real pharmacology.
MOTSC (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrially derived peptide first characterized by Lee et al. (2015, Cell Metabolism). Rodent and in vitro studies suggest it activates AMPK, improves insulin sensitivity, and may increase fatty acid oxidation. A small human study by Reynolds et al. (2021, Nature Aging) showed some metabolic improvements in older men, but the sample sizes are tiny and the data should not be treated as conclusive. The claim that it "gives you energy" is plausible at a cellular level but has not been validated in controlled human trials for that specific outcome.
The stacking rationale she describes, that two different pathways multiply results, is a hypothesis, not an established protocol. No published study has examined this combination.
What did they get wrong (or right)?
She got the receptor pharmacology of retatrutide broadly right. Calling it a GLP-1, GIP, and glucagon agonist is accurate, and the claim that it controls hunger hormones is consistent with published trial outcomes. Credit where it is due.
What she got wrong is more concerning. Her description of MOTSC as something that allows "glucose and the fat to get into the cell instead of storing it as fat" oversimplifies and partially misrepresents the mechanism. AMPK activation by MOTSC does not directly shuttle nutrients into cells the way insulin does. It primarily shifts cellular energy sensing toward catabolism, which is a different process than what she described.
Her repeated mispronunciation of retatrutide as "Reddit" is a minor issue, but the casual naming matters because viewers may search for information using incorrect terms and end up with inaccurate or dangerous sources.
More significantly, framing a two-compound peptide stack as a straightforward "game changer" without any mention of side effect profiles, the experimental status of MOTSC in humans, or the regulatory status of compounded retatrutide is a real omission. Retatrutide is not FDA-approved. Compounded versions exist in a complicated legal gray zone following FDA enforcement actions against compounded semaglutide and tirzepatide. Anyone considering this stack should understand that context before anything else.
What should you actually know?
The mechanistic logic here is not unreasonable, but the evidence gap between the logic and the claim is large. Retatrutide has solid Phase 2 data supporting weight loss, but it is not FDA-approved and compounded formulations carry regulatory uncertainty. MOTSC has promising preclinical and very early human data, but calling it an established fat-loss tool in 2024 overstates what the science actually shows.
The idea of combining a GLP-1/GIP/glucagon receptor agonist with a mitochondrial peptide that activates AMPK is mechanistically interesting. Researchers have explored AMPK activation as complementary to GLP-1 therapy in animal models. But interesting mechanisms do not equal proven outcomes in humans, and no study has tested this specific combination.
If you are considering peptide therapy for metabolic goals, the conversation should start with a licensed clinician who can review your metabolic panel, cardiovascular history, and current medications. The energy boost claim for MOTSC is not well-supported enough to use as a primary reason to add a second experimental compound to a stack. And any platform or provider who skips that conversation is not one you should trust with your health.